Collateral responses to classical cytotoxic chemotherapies are heterogeneous and sensitivities are sparse
<jats:title>Abstract</jats:title><jats:p>Chemotherapy resistance is a major obstacle to curing cancer patients. Combination drug regimens have shown promise as a method to overcome resistance; however, to date only some cancers have been cured with this method. Collateral sensitivi...
| Main Authors: | , , , |
|---|---|
| Other Authors: | |
| Format: | Article |
| Language: | English |
| Published: |
Springer Science and Business Media LLC
2022
|
| Online Access: | https://hdl.handle.net/1721.1/146809 |
| _version_ | 1811071794192318464 |
|---|---|
| author | Dalin, Simona Grauman-Boss, Beatrice Lauffenburger, Douglas A Hemann, Michael T |
| author2 | Massachusetts Institute of Technology. Department of Biology |
| author_facet | Massachusetts Institute of Technology. Department of Biology Dalin, Simona Grauman-Boss, Beatrice Lauffenburger, Douglas A Hemann, Michael T |
| author_sort | Dalin, Simona |
| collection | MIT |
| description | <jats:title>Abstract</jats:title><jats:p>Chemotherapy resistance is a major obstacle to curing cancer patients. Combination drug regimens have shown promise as a method to overcome resistance; however, to date only some cancers have been cured with this method. Collateral sensitivity—the phenomenon whereby resistance to one drug is co-occurrent with sensitivity to a second drug—has been gaining traction as a promising new concept to guide rational design of combination regimens. Here we evolved over 100 subclones of the Eµ-Myc; p19<jats:sup>ARF−/−</jats:sup> cell line to be resistant to one of four classical chemotherapy agents: doxorubicin, vincristine, paclitaxel, and cisplatin. We then surveyed collateral responses to acquisition of resistance to these agents. Although numerous collateral sensitivities have been documented for antibiotics and targeted cancer therapies, we observed only one collateral sensitivity: half of cell lines that acquired resistance to paclitaxel also acquired a collateral sensitivity to verapamil. However, we found that the mechanism of this collateral sensitivity was unrelated to the mechanism of paclitaxel resistance. Interestingly, we observed heterogeneity in the phenotypic response to acquisition of resistance to most of the drugs we tested, most notably for paclitaxel, suggesting the existence of multiple different states of resistance. Surprisingly, this phenotypic heterogeneity in paclitaxel resistant cell lines was unrelated to transcriptomic heterogeneity among those cell lines. These features of phenotypic and transcriptomic heterogeneity must be taken into account in future studies of treated tumor subclones and in design of chemotherapy combinations.</jats:p> |
| first_indexed | 2024-09-23T08:56:18Z |
| format | Article |
| id | mit-1721.1/146809 |
| institution | Massachusetts Institute of Technology |
| language | English |
| last_indexed | 2024-09-23T08:56:18Z |
| publishDate | 2022 |
| publisher | Springer Science and Business Media LLC |
| record_format | dspace |
| spelling | mit-1721.1/1468092022-12-09T03:41:43Z Collateral responses to classical cytotoxic chemotherapies are heterogeneous and sensitivities are sparse Dalin, Simona Grauman-Boss, Beatrice Lauffenburger, Douglas A Hemann, Michael T Massachusetts Institute of Technology. Department of Biology <jats:title>Abstract</jats:title><jats:p>Chemotherapy resistance is a major obstacle to curing cancer patients. Combination drug regimens have shown promise as a method to overcome resistance; however, to date only some cancers have been cured with this method. Collateral sensitivity—the phenomenon whereby resistance to one drug is co-occurrent with sensitivity to a second drug—has been gaining traction as a promising new concept to guide rational design of combination regimens. Here we evolved over 100 subclones of the Eµ-Myc; p19<jats:sup>ARF−/−</jats:sup> cell line to be resistant to one of four classical chemotherapy agents: doxorubicin, vincristine, paclitaxel, and cisplatin. We then surveyed collateral responses to acquisition of resistance to these agents. Although numerous collateral sensitivities have been documented for antibiotics and targeted cancer therapies, we observed only one collateral sensitivity: half of cell lines that acquired resistance to paclitaxel also acquired a collateral sensitivity to verapamil. However, we found that the mechanism of this collateral sensitivity was unrelated to the mechanism of paclitaxel resistance. Interestingly, we observed heterogeneity in the phenotypic response to acquisition of resistance to most of the drugs we tested, most notably for paclitaxel, suggesting the existence of multiple different states of resistance. Surprisingly, this phenotypic heterogeneity in paclitaxel resistant cell lines was unrelated to transcriptomic heterogeneity among those cell lines. These features of phenotypic and transcriptomic heterogeneity must be taken into account in future studies of treated tumor subclones and in design of chemotherapy combinations.</jats:p> 2022-12-08T19:42:10Z 2022-12-08T19:42:10Z 2022 2022-12-08T18:30:09Z Article http://purl.org/eprint/type/JournalArticle https://hdl.handle.net/1721.1/146809 Dalin, Simona, Grauman-Boss, Beatrice, Lauffenburger, Douglas A and Hemann, Michael T. 2022. "Collateral responses to classical cytotoxic chemotherapies are heterogeneous and sensitivities are sparse." Scientific Reports, 12 (1). en 10.1038/S41598-022-09319-1 Scientific Reports Creative Commons Attribution 4.0 International license https://creativecommons.org/licenses/by/4.0/ application/pdf Springer Science and Business Media LLC Scientific Reports |
| spellingShingle | Dalin, Simona Grauman-Boss, Beatrice Lauffenburger, Douglas A Hemann, Michael T Collateral responses to classical cytotoxic chemotherapies are heterogeneous and sensitivities are sparse |
| title | Collateral responses to classical cytotoxic chemotherapies are heterogeneous and sensitivities are sparse |
| title_full | Collateral responses to classical cytotoxic chemotherapies are heterogeneous and sensitivities are sparse |
| title_fullStr | Collateral responses to classical cytotoxic chemotherapies are heterogeneous and sensitivities are sparse |
| title_full_unstemmed | Collateral responses to classical cytotoxic chemotherapies are heterogeneous and sensitivities are sparse |
| title_short | Collateral responses to classical cytotoxic chemotherapies are heterogeneous and sensitivities are sparse |
| title_sort | collateral responses to classical cytotoxic chemotherapies are heterogeneous and sensitivities are sparse |
| url | https://hdl.handle.net/1721.1/146809 |
| work_keys_str_mv | AT dalinsimona collateralresponsestoclassicalcytotoxicchemotherapiesareheterogeneousandsensitivitiesaresparse AT graumanbossbeatrice collateralresponsestoclassicalcytotoxicchemotherapiesareheterogeneousandsensitivitiesaresparse AT lauffenburgerdouglasa collateralresponsestoclassicalcytotoxicchemotherapiesareheterogeneousandsensitivitiesaresparse AT hemannmichaelt collateralresponsestoclassicalcytotoxicchemotherapiesareheterogeneousandsensitivitiesaresparse |